Tests shorter-course radiotherapy after prostate surgery for prostate cancer
Tests shorter radiation courses after prostate removal in adults with prostate cancer.
Plain-language title generated from the registry record
Registry title: Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- The First Affiliated Hospital of Naval Medical UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Changhai Hospital
- Trial code
- NCT06335693
- Record updated
- 28 March 2024
- Original description
Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the safety and feasibility of adjuvant hypofractionated radiotherapy following radical prostatectomy for prostate cancer.Read full original descriptionShow less
Safety and Efficacy Study of Adjuvant Hypofractionated Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the safety and feasibility of adjuvant hypofractionated radiotherapy following radical prostatectomy for prostate cancer.
Inclusion: ECOG performance status 0-2; Pathologically confirmed prostate cancer and completion of radical prostatectomy; Postoperative pathological staging pT 3a, pT 3b, pT 4, surgical margins (+) or N1; or serum PSA ≥0.1ng/ml at 6 weeks postoperatively; or serum PSA <0.1ng/ml at 6 weeks postoperatively, with two consecutive persistently elevated PSA (≥0.1ng/ml) without signs of metastasis on clinical imaging (whole-body bone scan (ECT), magnetic resonance imaging (MRI), 68Ga PSMA PET/CT, etc.) ; Expected survival time >5 years; Voluntarily accepted this experimental study protocol after being informed of the available treatment options.
Exclusion: Patients who participated in other clinical trials that were repugnant to the intervention of this trial within 4 weeks prior to the start of this trial; Patients with radiotherapy-related contraindications; Patients with a history of pelvic and abdominal radiotherapy; Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis; Patients who are deemed unfit to participate in this clinical trial in the judgement of the investigator, for instance, patients with serious systemic diseases that, in the judgement of the investigator, may interfere with the treatment and evaluation of this trial and its compliance, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immunological, urological and other systemic diseases; Patients with poor recovery of continence after radical prostatectomy; Patients who cannot provide written informed consent and have poor adherence to treatment.